

Remicade (Infliximab) Patient Referral and Prescription Sheet

Patient Information										
Patient Name:							Date:			
DOB:							Height:		□ inches □ cm	
Allergies:							Weight:		🗆 lbs 🖵 kg	
Primary Diagnosis										
Diagnosis ICD-					Diagnosis					ICD-10
Crohn's Disease of small intestine without complications				K50.00	Crohn's Disease of large intestine without complications K50.10					К50.10
Crohn's Disease, unspecified without complications K50.90					Ulcerative Chronic pancolitis without complications K51.0					K51.00
Plaque Psoriasis L40.0					□ Psoriatic Psoriasis L40.52					L40.52
Rheumatoid arth	M06.9	Ankylosing Spondylitis M45.9					M45.9			
Ulcerative Colitis	K51.90	□ Other								
Medication Order										
Carter Remicade	Renflexis	🗅 Avsola	🗆 Infl	liximab	Inflectra	[J Zymfentra	Refills x one year		
Dosing: Initiation: Administermg/kg IV over at least two hours at weeks 0, 2 and 6 per protocol signature unless indicated below Initiation: Administermg/kg IV overminutes everyweeks indicated below Round to the nearest 100mg vial size OR exact dose of:mg weeks 120mg SC every 2 weeksRefills OtherRefills Nursing OrdersRefills Skilled nursing visit for clinical assessment, administration of medication. Initiate plan of treatment for ongoing nursing services. Insert or ac maintain access device as indicated in Ancillary Orders. Remove peripheral IV or access from implanted VAD when infusion is completed. Pre-medications: IV Flush Orders: Diphenhydramine: 25mg PO 30 min pre-infusion Peripheral: NS 1-3 mL before/after use Acctaminophen: 650mg PO 30 min pre-infusion Implanted VAD: NS 5 to 10 mL before/after use and 10 mL post-lab d Heparin (100 unit/mL) 3 to 5 mL final flush Other pre-meds: CVAD: NS 5 to 10 mL before/after use and 10 mL post-lab d Heparin (10 units/mL) 3 to 5 mL final flush								e and 10 mL po	ost-	
Anaphylaxis Protocol: Epinephrine Auto-Injector dual pack: Adult: 0.3mg Children: 0.15 mg Administer epinephrine IM in the event of anaphylaxis. May repeat x 1 as needed, Call 911. Refill x 1yr										
Therapy Specific Documentation Other Required Documentation										
Please include the CMP CBC LFTs CRP Infliximab Trough Other	 Patient Demographics – include insurance information. We will obtain authorization unless the insurance dictates otherwise. H & P OR progress note(s) Medication List- Please list past and present DMARDS/biologics below with dates of discontinue, if applicable Hepatitis B Surface Antigen Hepatitis B Core Antibody Total (not Core IgM) QuantiFERON-TB Gold 									
Provider Information										
Provider Name:					P	Provider Phone:				
Provider NPI:					P	Provider Fax:				
Provider Address:										
authorize KabaEurian and ite representatives to act as an agent and initiate and everyte any insurance prior authorization presess for this presentian and any future refills of the same presentation										

I authorize KabaFusion and its representatives to act as an agent and initiate and execute any insurance prior authorization process for this prescription and any future refills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to KabaFusion.

Prescriber Signature: _

Date: ____

CONFIDENTIALITY NOTICE: The following includes confidential, proprietary information that is the sole exclusive property of KabaFusion Holdings, LLC. No rights in, relating to, or derived from such information are assigned or otherwise transferred by this document, and the recipient of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is strictly prohibited. This message, together with any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender immediately by telephone or by return fax and shred this document along with any other documents. Thank you.